Edition:
United States

Livzon Pharmaceutical Group Inc (000513.SZ)

000513.SZ on Shenzhen Stock Exchange

67.91CNY
15 Dec 2017
Change (% chg)

¥-1.91 (-2.74%)
Prev Close
¥69.82
Open
¥69.24
Day's High
¥69.80
Day's Low
¥67.38
Volume
5,471,523
Avg. Vol
5,225,342
52-wk High
¥77.77
52-wk Low
¥40.12

Chart for

About

LIVZON PHARMACEUTICAL GROUP INC. is a China-based company principally engaged in research, development, production and distribution of pharmaceutical products. The Company primarily offers western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. The Company’s... (more)

Overall

Beta: 0.73
Market Cap(Mil.): ¥34,009.42
Shares Outstanding(Mil.): 553.23
Dividend: 0.38
Yield (%): 0.57

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection

Nov 03 2017

BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept

* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan

Oct 25 2017

BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln

* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Livzon Pharmaceutical Group units receive approval for drug clinical trials

* Says its units received drug clinical trials approval for drug, Triptorelin Acetate Microspheres for Injection

Sep 18 2017

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for antineoplastic, Paclitaxel polymeric micelles for injection

Sep 11 2017

BRIEF-Livzon Pharmaceutical Group says change of accounting policies

* Says it changes accounting policies regarding government subsidy, non-current assets, disposal groups and discontinued operations

Aug 22 2017

BRIEF-Livzon Pharmaceutical sees Jan-Sept net profit attributable between RMB4.23 bln-RMB4.27 bln

* Sees Jan-Sept 2017 net profit attributable to rise 587.86 pct - 594.55 pct to RMB 4,228.7864 million-RMB 4,269.9288 million Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

Aug 22 2017

BRIEF-Livzon Pharmaceutical updates on releasing of pledged shares held by controlling shareholder

* Received notice from Topsino that Topsino released pledge of its 16.3 million H shares of co from Nanyang Commercial Bank Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Livzon Pharmaceutical announces net profit attributable for HY ended 30 June 2017

* Preliminary net profit attributable for six months ended 30 June 2017 about rmb 490.9 million-rmb531.8 million versus rmb409.1 million last year Source text for Eikon: Further company coverage:

Jul 11 2017

BRIEF-Livzon Pharma expects H1 net profit to rise 20-30 pct y/y

* Says it expects H1 net profit to rise 20-30 percent y/y to 490.9-531.8 million yuan ($72.20-$78.21 million)

Jul 11 2017

Earnings vs. Estimates